Connecticut Medical Marijuana Program Resources

• Cancer (Effective 2012)
• Glaucoma (Effective 2012)
• Positive Status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome (Effective 2012)
• Parkinson’s Disease (Effective 2012)
• Multiple Sclerosis (Effective 2012)
• Damage to the Nervous Tissue of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)
• Epilepsy (Effective 2012)
• Cachexia (Effective 2012)
• Wasting Syndrome (Effective 2012)
• Crohn’s Disease (Effective 2012)
• Post-Traumatic Stress Disorder (Effective 2012)
• Sickle Cell Disease (Effective 2016)*
• Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)*
• Severe Psoriasis and Psoriatic Arthritis (Effective 2016)*
• Amyotrophic Lateral Sclerosis (Effective 2016)*
• Ulcerative Colitis (Effective 2016)*
• Complex Regional Pain Syndrome, Type 1 and Type II (Effective 2016)*
• Cerebral Palsy (Effective 2016)
• Cystic Fibrosis (Effective 2016)
• Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
• Terminal Illness Requiring End-Of-Life Care (Effective 2016)
• Uncontrolled Intractable Seizure Disorder (Effective 2016)
• Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)*
• Severe Rheumatoid Arthritis (Effective 2018)*
• Post Herpetic Neuralgia (Effective 2018)*
• Hydrocephalus with Intractable Headache (Effective 2018)*
• Intractable Headache Syndromes (Effective 2018)*
• Neuropathic Facial Pain (Effective 2018)*
• Muscular Dystrophy (Effective 2018)*
• Osteogenesis Imperfecta (Effective 2018)*
• Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)*
• Interstitial Cystitis (Effective 2019)*
• MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)*
• Vulvodynia and Vulvar Burning (Effective 2019)*
• Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
• Tourette Syndrome (Effective 2019)*
• Chronic Pain of at least 6 months duration associated with a specified underlying chronic condition refractory to other treatment intervention (Effective 2020)*
• Ehlers-Danlos Syndrome Associated with Chronic Pain (Effective 2020)*
• Chronic Pancreatitis (Effective 2021)*
• Movement disorders associated with Huntington Disease (Effective 2021)^

For Patients Under 18, Debilitating Medical Conditions Include:

• Cerebral Palsy (Effective 2016)
• Cystic Fibrosis (Effective 2016)
• Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
• Severe Epilepsy (Effective 2016)
• Terminal Illness Requiring End-Of-Life Care (Effective 2016)
• Uncontrolled Intractable Seizure Disorder (Effective 2016)
• Muscular Dystrophy (Effective 2018)*
• Osteogenesis Imperfecta (Effective 2018)*
• Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
• Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)*
• Chronic Pancreatitis for patients whose pain is recalcitrant to standard medical management (Effective 2021)*

* Conditions were approved by the Regulation Review Committee via the recommendation of the Board of Physicians and Commissioner of Consumer Protection. ^ Condition was approved, pursuant to the Public Act 21-1 the Responsible and Equitable Regulations of Adult-Use Cannabis Act, upon publication on the Department of Consumer Protections website.Qualifications for a Registration Certificate:

• Qualifying patient must be a Connecticut resident.
• Qualifying patient cannot be an inmate confined in a correctional institution or facility under the supervision of the Connecticut Department of Corrections.